Citations

Citations to this article as recorded by  

• Adipose tissue inflammation linked to obesity: A review of current understanding, therapies and relevance of phyto-therapeutics
  Christiana Eleojo Aruwa, Saheed Sabiu
  Heliyon.2024; 10(1): e23114.     CrossRef
• Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial
  Liv Vernstrøm, Søren Gullaksen, Steffen S. Sørensen, Kristian L. Funck, Esben Laugesen, Per L. Poulsen
  Diabetes, Obesity and Metabolism.2024; 26(5): 1624.     CrossRef
• Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
  Daniel de Luis Román, Juana Carretero Gómez, José Manuel García-Almeida, Fernando Garrachón Vallo, German Guzmán Rolo, Juan José López Gómez, Francisco José Tarazona-Santabalbina, Alejandro Sanz-Paris
  Reviews in Endocrine and Metabolic Disorders.2024;[Epub]     CrossRef
• The Current Landscape of Pharmacotherapies for Sarcopenia
  Gulistan Bahat, Serdar Ozkok
  Drugs & Aging.2024; 41(2): 83.     CrossRef
• Vascular Aging: Assessment and Intervention
  Ao Li, Jinhua Yan, Ya Zhao, Zhenping Yu, Shane Tian, Abdul Haseeb Khan, Yuanzheng Zhu, Andong Wu, Cuntai Zhang, Xiao-Li Tian
  Clinical Interventions in Aging.2023; Volume 18: 1373.     CrossRef
• The Effect of Additional Treatment with Empagliflozin or Semaglutide on Endothelial Function and Arterial Stiffness in Subjects with Type 1 Diabetes Mellitus—ENDIS Study
  Maja Preložnik Navodnik, Andrej Janež, Ivan Žuran
  Pharmaceutics.2023; 15(7): 1945.     CrossRef
• Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment
  Christian Salom Vendrell, Elisa García Tercero, Juan Bautista Moro Hernández, Bernardo Abel Cedeno-Veloz
  Nutrients.2023; 15(19): 4149.     CrossRef
• Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
  Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
  Sydney S. Wilbon, Mikhail G. Kolonin
  Cells.2023; 13(1): 65.     CrossRef
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
  Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
  Medicines.2022; 9(9): 47.     CrossRef
• Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
  Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-H
  Journal of Clinical Medicine.2022; 12(1): 145.     CrossRef
• The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms
  Elena Massimino, Anna Izzo, Gabriele Riccardi, Giuseppe Della Pepa
  Cells.2021; 10(8): 1958.     CrossRef
• Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
  Xueli Zhang, Yi Zhao, Shuobing Chen, Hua Shao
  Journal of Cachexia, Sarcopenia and Muscle.2021; 12(6): 1368.     CrossRef
• Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review
  Sofia Antoniou, Katerina K K Naka, Marios Papadakis, Aris Bechlioulis, Agathocles Tsatsoulis, Lampros K Michalis, Stelios Tigas
  World Journal of Diabetes.2021; 12(11): 1856.     CrossRef
• A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
  Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
  Endocrinology and Metabolism.2019; 34(3): 247.     CrossRef
• The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis
  Takahiro Yajima, Kumiko Yajima, Hiroshi Takahashi, Keigo Yasuda
  Journal of Diabetes and its Complications.2018; 32(8): 759.     CrossRef
• Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis
  Konstantinos Batzias, Alexios S. Antonopoulos, Evangelos Oikonomou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Chara-Vasiliki Mistakidi, Marina Noutsou, Niki Katsiki, Periklis Karopoulos, Georgios Charalambous, Anastasia Thanopoulou, N
  Journal of Diabetes Research.2018; 2018: 1.     CrossRef
• Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes
  N. González, Z. Moreno-Villegas, A. González-Bris, J. Egido, Ó. Lorenzo
  Cardiovascular Diabetology.2017;[Epub]     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
• Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
  Dong-Mee Lim, Keun-Young Park, Won-Min Hwang, Ju-Young Kim, Byung-Joon Kim
  Experimental and Therapeutic Medicine.2017; 13(5): 2558.     CrossRef
• Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists
  Qiuhe Ji
  Clinical Therapeutics.2017; 39(6): 1244.     CrossRef
• Differential Role of Adipose Tissues in Obesity and Related Metabolic and Vascular Complications
  Almudena Gómez-Hernández, Nuria Beneit, Sabela Díaz-Castroverde, Óscar Escribano
  International Journal of Endocrinology.2016; 2016: 1.     CrossRef

Citations

Citations to this article as recorded by  

• Novel GLP-1(28–36) amide-derived hybrid peptide A3 with weight loss and hypoglycemic activities
  Chen Wang, Binbin Gong, Qianqian Zhu, Jing Han, Lidan Sun
  European Journal of Pharmacology.2023; 961: 176200.     CrossRef
• Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake
  Anneke Kuipers, Márta Balaskó, Erika Pétervári, Andreas Koller, Susanne M. Brunner, Gert N. Moll, Barbara Kofler
  Neurotherapeutics.2021; 18(4): 2737.     CrossRef
• Low-Dose Decitabine Assists Human Umbilical Cord-Derived Mesenchymal Stem Cells in ProtectingβCells via the Modulation of the Macrophage Phenotype in Type 2 Diabetic Mice
  Jing Xue, Yu Cheng, Haojie Hao, Jieqing Gao, Yaqi Yin, Songyan Yu, Junyan Zou, Jiejie Liu, Qi Zhang, Yiming Mu
  Stem Cells International.2020; 2020: 1.     CrossRef
• DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus
  W. Wang, X. Wen, W. Duan, X. Wang, Y. Chen, J. Dong, Z. Yang, J. Fang, Z. Zhou, G. Yao, Y. Fang, Y. Huang
  Journal of Endocrinological Investigation.2020; 43(5): 653.     CrossRef
• Evolutionary and Comparative Genomics to Drive Rational Drug Design, with Particular Focus on Neuropeptide Seven-Transmembrane Receptors
  Michael Furlong, Jae Young Seong
  Biomolecules & Therapeutics.2017; 25(1): 57.     CrossRef
• Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial
  Li Shi, Jing Zhu, Ping Yang, Xiaoqiang Tang, Wenlong Yu, Changjie Pan, Moyu Shen, Dalong Zhu, Jinluo Cheng, Xinhua Ye
  Obesity Research & Clinical Practice.2017; 11(5): 607.     CrossRef
• Mesenchymal stem cell therapy in type 2 diabetes mellitus
  Li Zang, Haojie Hao, Jiejie Liu, Yijun Li, Weidong Han, Yiming Mu
  Diabetology & Metabolic Syndrome.2017;[Epub]     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• Development of Spexin-based Human Galanin Receptor Type II-Specific Agonists with Increased Stability in Serum and Anxiolytic Effect in Mice
  Arfaxad Reyes-Alcaraz, Yoo-Na Lee, Gi Hoon Son, Nam Hoon Kim, Dong-Kyu Kim, Seongsik Yun, Dong-Hoon Kim, Jong-Ik Hwang, Jae Young Seong
  Scientific Reports.2016;[Epub]     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
• Biased signalling: the instinctive skill of the cell in the selection of appropriate signalling pathways
  Ying Liu, Yang Yang, Richard Ward, Su An, Xiao-Xi Guo, Wei Li, Tian-Rui Xu
  Biochemical Journal.2015; 470(2): 155.     CrossRef

Glucagon-like peptide 1 (GLP-1) is secreted from enteroendocrine L-cells in response to oral nutrient intake and elicits glucose-stimulated insulin secretion while suppressing glucagon secretion. It also slows gastric emptying, which contributes to decreased postprandial glycemic excursions. In the 1990s, chronic subcutaneous infusion of GLP-1 was found to lower blood glucose levels in patients with type 2 diabetes. However, GLP-1's very short half-life, arising from cleavage by the enzyme dipeptidyl peptidase 4 (DPP-4) and glomerular filtration by the kidneys, presented challenges for clinical use. Hence, DPP-4 inhibitors were developed, as well as several GLP-1 analogs engineered to circumvent DPP-4-mediated breakdown and/or rapid renal elimination. Three categories of GLP-1 analogs, are being developed and/or are in clinical use: short-acting, long-acting, and prolonged-acting GLP-1 analogs. Each class has different plasma half-lives, molecular size, and homology to native GLP-1, and consequently different characteristic effects on glucose metabolism. In this article, we review current clinical data derived from each class of GLP-1 analogs, and consider the clinical effects reported for each category in recent head to head comparison studies. Given the relatively brief clinical history of these compounds, we also highlight several important efficacy and safety issues which will require further investigation.

Citations

Citations to this article as recorded by  

• The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
  Jhih-Syuan Liu, Sheng-Chiang Su, Feng-Chih Kuo, Peng-Fei Li, Chia-Luen Huang, Li-Ju Ho, Kuan-Chan Chen, Yi-Chen Liu, Chih-Ping Lin, An-Che Cheng, Chien-Hsing Lee, Fu-Huang Lin, Yi-Jen Hung, Hsin-Ya Liu, Chieh-Hua Lu, Chang-Hsun Hsieh
  Medicine.2023; 102(10): e33167.     CrossRef
• Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
  Mariya Kalinkova, Tanya Kadiyska, Teodora Handjieva-Darlenska
  Pharmacia.2023; 70(2): 383.     CrossRef
• Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation
  Irem Mert, Ayhan Cetinkaya, Mujgan Gurler, Canan Akünal Turel, Humeyra Celik, Ibrahim Ethem Torun, Idris Turel
  Inflammopharmacology.2022; 30(3): 1093.     CrossRef
• Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
  Chuanmin Bai, Yujun Wang, Zhi Niu, Yaxin Guan, Jingshan Huang, Xin Nian, Fan Zuo, Juan Zhao, Tsutomu Kazumi, Bin Wu
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
  Hun Jee Choe, Young Min Cho
  Endocrinology and Metabolism.2021; 36(1): 22.     CrossRef
• Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
  Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli
  International Journal of Endocrinology.2021; 2021: 1.     CrossRef
• Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
  Zeinab A. Saad, Dina M. Khodeer, Sawsan A. Zaitone, Amal A.M. Ahmed, Yasser M. Moustafa
  Life Sciences.2020; 253: 117725.     CrossRef
• Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
  Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
  Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
• Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis
  Se Hee Min, Jeong‐Hwa Yoon, Seokyung Hahn, Young Min Cho
  Journal of Diabetes Investigation.2018; 9(4): 893.     CrossRef
• Glucagon-like peptide-1 affects human umbilical vein endothelial cells in high glucose by the PI3K/Akt/eNOS signaling pathway
  Jie Wu, Pingfan Guo, Tianmin He, Fanggang Cai
  Turkish Journal of Biochemistry.2018; 43(2): 119.     CrossRef
• What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
  Wing B. Chan, Andrea Luk, Wing S. Chow, Vincent T.F. Yeung
  Journal of Diabetes.2017; 9(6): 562.     CrossRef
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
  L. Østergaard, Christian S. Frandsen, S. Madsbad
  Expert Review of Clinical Pharmacology.2016; 9(2): 241.     CrossRef
• Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
  Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
  Diabetes/Metabolism Research and Reviews.2016; 32(8): 776.     CrossRef
• Glucagon‐like peptide‐1(GLP‐1) receptor agonists: potential to reduce fracture risk in diabetic patients?
  Guojing Luo, Hong Liu, Hongyun Lu
  British Journal of Clinical Pharmacology.2016; 81(1): 78.     CrossRef
• Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?
  Sten Madsbad
  Journal of Diabetes and its Complications.2016; 30(2): 374.     CrossRef
• Risk assessment and management of post-transplant diabetes mellitus
  Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
  Metabolism.2016; 65(10): 1559.     CrossRef
• Recent advances in oral delivery of peptide hormones
  Pegah Varamini, Istvan Toth
  Expert Opinion on Drug Delivery.2016; 13(4): 507.     CrossRef
• Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
  Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
  PLOS ONE.2016; 11(12): e0166913.     CrossRef
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
  Sten Madsbad
  Diabetes, Obesity and Metabolism.2016; 18(4): 317.     CrossRef
• Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
  Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
  Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
• Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
  P. D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M. C. Carr
  Diabetes, Obesity and Metabolism.2015; 17(2): 179.     CrossRef
• Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
  Jaime A. Davidson
  Postgraduate Medicine.2015; 127(8): 827.     CrossRef
• GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
  Jia Liu, Guang Wang, Yumei Jia, Yuan Xu
  Diabetes/Metabolism Research and Reviews.2015; 31(4): 329.     CrossRef
• Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial
  M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang, B. Y. Cha
  Diabetes, Obesity and Metabolism.2015; 17(3): 309.     CrossRef
• Incretin physiology and pathophysiology from an Asian perspective
  Young Min Cho
  Journal of Diabetes Investigation.2015; 6(5): 495.     CrossRef
• Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
  Antoni Sicras-Mainar, Ruth Navarro-Artieda
  Diabetes & Metabolism Journal.2015; 39(2): 173.     CrossRef
• Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
  Se Hee Min, Young Min Cho
  The Journal of Korean Diabetes.2015; 16(4): 252.     CrossRef
• Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
  Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
  Islets.2015; 7(5): e1129096.     CrossRef
• Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
  Mi Yeon Kang, Tae Jung Oh, Young Min Cho
  Endocrinology and Metabolism.2015; 30(2): 216.     CrossRef
• Interleukin-6 CpG Methylation and Body Weight Correlate Differently in Type 2 Diabetes Patients Compared to Obese and Lean Controls
  Eva Aumueller, Marlene Remely, Hanna Baeck, Berit Hippe, Helmut Brath, Alexander G. Haslberger
  Lifestyle Genomics.2015; 8(1): 26.     CrossRef
• The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
  Hirohisa Onuma, Kouichi Inukai, Atsuko Kitahara, Rie Moriya, Susumu Nishida, Toshiaki Tanaka, Hidenori Katsuta, Kazuto Takahashi, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida
  Biochemical and Biophysical Research Communications.2014; 451(2): 339.     CrossRef
• Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
  Won-Young Lee
  Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
• Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
  Dorit Naot, Jillian Cornish
  Frontiers in Endocrinology.2014;[Epub]     CrossRef
• Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
  Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, Alexandros Kokkinos, Nicholas Tentolouris, Ioannis Ioannidis
  Journal of Diabetes Research.2014; 2014: 1.     CrossRef
• The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
  Mark F McCarty, James J DiNicolantonio
  Open Heart.2014; 1(1): e000103.     CrossRef
• Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
  J.J. Gorgojo-Martínez
  Hipertensión y Riesgo Vascular.2014; 31(2): 45.     CrossRef
• Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens
  Thomas B. Repas
  Journal of Osteopathic Medicine.2014; 114(s52): 14.     CrossRef